Vericiguat

Details

Vericiguat (brand name: Verquvo) is an oral soluble guanylate cyclase (sGC) stimulator — the first drug in its class with a positive phase 3 outcomes trial in heart failure. It is approved for adults with symptomatic chronic HFrEF (LVEF <45%) who have experienced recent worsening despite guideline-directed medical therapy. It represents a mechanistic departure from the neurohormonal axis that underpins all four pillars of standard HFrEF therapy.

Key Facts

Mechanism

• Dual action on sGC: (1) Directly stimulates sGC via a binding site independent of nitric oxide — restores sGC activity even when NO availability is severely impaired by endothelial dysfunction; (2) Sensitizes sGC to endogenous NO by stabilizing NO binding to the haem site. (sources/vericiguat-victoria-nejm-2020, rating: very high)
• Net effect: Increased cyclic GMP (cGMP) → vasodilation, anti-fibrotic, anti-inflammatory, and anti-hypertrophic cardiac effects.
• Pathophysiological rationale: In HF, endothelial dysfunction + reactive oxygen species reduce NO bioavailability → relative sGC deficiency → ↓cGMP production. Vericiguat corrects this downstream deficit regardless of upstream NO status. (sources/vericiguat-victoria-nejm-2020, rating: very high)
• Mechanistic distinction from related drug classes:
  • Nitrates: Donate exogenous NO (require intact sGC and are tolerance-prone)
  • PDE5 inhibitors (sildenafil, tadalafil): Prevent cGMP degradation (require pre-existing cGMP generation)
  • Vericiguat: Stimulates cGMP synthesis directly, independent of NO — active even in severe endothelial dysfunction

VICTORIA Trial — Primary Evidence

Phase 3, randomized, double-blind, placebo-controlled (n=5,050; 42 countries; median follow-up 10.8 months). (sources/vericiguat-victoria-nejm-2020, rating: very high)

Population (high-risk worsening HFrEF):

• NYHA II–IV; LVEF <45%; mean EF 29%; mean age 67 years; 24% women
• Median NT-proBNP 2816 pg/mL; 41% NYHA Class III
• Evidence of recent worsening: hospitalized within 3 months (most patients), hospitalized 3–6 months prior, or IV diuretics within 3 months
• Background therapy: 60% triple therapy; 15% sacubitril-valsartan; 32% ICD/CRT
• Very few patients on SGLT2i (enrolled 2016–2018 — before broad SGLT2i adoption in HF)

Dosing: Starting dose 2.5 mg OD → 5 mg → target 10 mg OD (guided by BP and symptoms); 90.3% at 10-mg target at ~12 months.

Key results:

• ARR: ~4.2 events per 100 patient-years
• NNT: ~24 for 1 year to prevent one primary-outcome event (~28 by 12-month KM estimates)
• Benefit emerged at ~3 months and persisted throughout
• Effect consistent across most subgroups including patients receiving sacubitril-valsartan
• Interaction: Attenuated benefit in subgroups with very elevated NT-proBNP and older age — possible signal for HF too advanced for benefit

Safety Profile

• Symptomatic hypotension: 9.1% vs 7.9% (P=0.12)
• Syncope: 4.0% vs 3.5% (P=0.30)
• Anemia: 7.6% vs 5.7% (class effect; Hb decline −0.38 vs −0.14 g/dL at 16 weeks; 1.6% serious vs 0.9%)
• Slight SBP decline over first 16 weeks, returned to baseline
• No significant difference in renal function or electrolyte adverse events

Guideline Recommendations

• AHA 2022: COR 2b, LOE B-R — "may be reasonable" for NYHA II–IV HFrEF with recent worsening event despite GDMT. (sources/HF-AHA-2022, rating: very high)
• ESC 2021: Class IIb — may be considered to reduce HF hospitalization or CV death in symptomatic patients. (sources/HF-ESC-2021, rating: very high)
• Lower recommendation class (2b/IIb) than the four pillars (COR 1/Class I) reflects modest relative benefit and absence of mortality reduction.

Key Contraindications / Drug Interactions

• Systolic BP <100 mmHg (exclusion criterion in VICTORIA)
• Concurrent long-acting nitrates — risk of excessive hypotension; pharmacodynamic overlap (both ↑cGMP axis)
• PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — risk of excessive hypotension; pharmacodynamic overlap
• Other sGC stimulators (riociguat) — combination contraindicated
• Caution with short-acting nitrates; VICTORIA excluded patients on long-acting nitrates

Contradictions / Open Questions

• No all-cause mortality benefit: VICTORIA showed HR 0.95 (P=0.38) for all-cause death. Short median follow-up (10.8 months) may have been insufficient — mortality benefit of other HF drugs typically emerges later. Whether longer follow-up would reveal mortality benefit is unknown. (sources/vericiguat-victoria-nejm-2020, rating: very high)
• Unknown incremental benefit over 4-pillar GDMT with SGLT2i: Trial enrolled 2016–2018 with very few patients on SGLT2i. The modern standard of care includes SGLT2i as a fourth pillar (COR 1A). Whether vericiguat provides additional benefit on top of full 4-pillar therapy (including SGLT2i) is unresolved. (sources/vericiguat-victoria-nejm-2020)
• Very elevated NT-proBNP subgroup: Apparent attenuation of benefit at highest NT-proBNP levels raises the question of whether these patients have HF too advanced for vericiguat to be effective — versus play of chance. Concurrent advanced age and reduced renal function in this subgroup confound interpretation. (sources/vericiguat-victoria-nejm-2020)
• sGC stimulation failed in HFpEF (RELAX, VITALITY, SOCRATES): Related pharmacological approaches targeting the cGMP axis (PDE5i in HFpEF, sGC stimulation in HFpEF) consistently failed. VICTORIA's positive result is specific to worsening HFrEF — not a validation of the cGMP axis across all HF phenotypes. See concepts/Titin-PTMs for context. (sources/HF-AHA-2022)

Connections

• Related to entities/Heart-Failure
• Related to entities/DCM
• Related to entities/HFpEF — contrast: cGMP-targeting drugs failed in HFpEF
• Related to concepts/Titin-PTMs — cGMP-PKG axis and its HFpEF failures contextualise VICTORIA's HFrEF-specific benefit

Sources

• sources/vericiguat-victoria-nejm-2020
• sources/HF-AHA-2022
• sources/HF-ESC-2021